Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies DB, Sandler BJ, Sznol M, Chen L. Flies DB, et al. Among authors: sznol m. Yale J Biol Med. 2011 Dec;84(4):409-21. Yale J Biol Med. 2011. PMID: 22180678 Free PMC article. Review.
T-cell adoptive immunotherapy: moving ahead by going in a circle.
Sznol M. Sznol M. Cancer J. 2000 Mar-Apr;6(2):61-3. Cancer J. 2000. PMID: 11069219 Review. No abstract available.
Immunotherapy for cancer: focusing on developing treatments rather than drugs.
Sznol M. Sznol M. Curr Opin Investig Drugs. 2001 Jul;2(7):957-8. Curr Opin Investig Drugs. 2001. PMID: 11757798 Review. No abstract available.
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M. Murren J, et al. Among authors: sznol m. Clin Cancer Res. 2003 Sep 15;9(11):4092-100. Clin Cancer Res. 2003. PMID: 14519631 Clinical Trial.
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. McCarthy MM, et al. Among authors: sznol m. Clin Cancer Res. 2005 Jul 15;11(14):5188-94. doi: 10.1158/1078-0432.CCR-05-0158. Clin Cancer Res. 2005. PMID: 16033835
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. McCarthy MM, et al. Among authors: sznol m. Clin Cancer Res. 2006 Jun 15;12(12):3856-63. doi: 10.1158/1078-0432.CCR-06-0190. Clin Cancer Res. 2006. PMID: 16778114 Free PMC article.
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Acquavella N, et al. Among authors: sznol m. J Immunother. 2008 Jul-Aug;31(6):569-76. doi: 10.1097/CJI.0b013e318177a4ba. J Immunother. 2008. PMID: 18528297
Betting on immunotherapy for melanoma.
Sznol M. Sznol M. Curr Oncol Rep. 2009 Sep;11(5):397-404. doi: 10.1007/s11912-009-0053-z. Curr Oncol Rep. 2009. PMID: 19679015 Review.
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. Jilaveanu LB, et al. Among authors: sznol m. Clin Cancer Res. 2009 Sep 15;15(18):5704-13. doi: 10.1158/1078-0432.CCR-09-0198. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737955 Free PMC article.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. Halaban R, et al. Among authors: sznol m. Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200. doi: 10.1111/j.1755-148X.2010.00685.x. Epub 2010 Feb 10. Pigment Cell Melanoma Res. 2010. PMID: 20149136 Free PMC article.
201 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback